HAT1 and melanoma: Melanoma cells expressing either NS or HAT1 shRNAs (HAT1 knockdown) were then tested for their sensitivity to the BRAFi vemurafenib, in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based short-term cell-survival assay.